Rationale for use of aripiprazole for alcohol dependence treatment

Drugs of the Future

Volumn 28, Issue 12, 2003, Pages 1227-1235

  Kenna, George A ^a,b  

^a Kent Hospital   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; OLANZAPINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; TIAPRIDE;

ALCOHOLISM; DIABETES MELLITUS; DOPAMINERGIC SYSTEM; DRINKING BEHAVIOR; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; REVIEW; SEROTONINERGIC SYSTEM;

EID: 0442325275     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.12.857392     Document Type: Review

References (113)

1. World Health Organization, Global Status Report on Alcohol, Geneva, Switzerland, 1999.
2. Grant, B.F., Harford T.C., Dawson, D.A. et al. Prevalence of DSM-IV alcohol abuse and dependence: United States, 1992. Alcohol Health Res World 1994, 18: 243-8.
3. Grant, B.F. Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States: results of the National Longitudinal Alcohol Epidemiologic Survey. J Stud Alcohol 1997, 58: 464-73.
4. Regier, D.A., Farmer, M.E., Rae, D.S. et al. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990, 264: 2511-18.
5. National Institute on Alcohol Abuse and Alcoholism. Tenth Special Report to the U.S. Congress on Alcohol and Health. U.S. Department of Health and Human Services: Washington, DC 2000.
6. Swift, R.M. Drug therapy in alcohol dependence. N Engl J Med 1999, 340: 1482-90.
7. Miller, W.R., Walters, S.T., Bennett, M.E. How effective is alcoholism treatment in the United States? J Stud Alcohol 2001, 62: 211-20.
8. DiChiara, G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 1995, 38: 95-137.
9. Kenna, G.A., Swift, R.M. Pharmacotherapies for alcohol dependence. U.S. Pharmacist, in press.
10. Fuller, R.K., Branchey, L., Brightwell, D.R. Disulfiram treatment of alcoholism. A Veterans Administration Cooperative Study. JAMA 1986, 256: 1449-55.
11. Aguirre, J.C., Del Arbol, J.L., Raya, J., Ruiz-Requena, M.E., Rico Irles, J. Plasma beta-endorphin levels in chronic alcoholics. Alcohol 1990, 7: 409-12.
12. Gianoulakis, C., Beliveau, D., Angelogianni, P. et al. Different pituitary β-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci 1989, 45: 1097-109.
13. Swift, R.M., Whelihan, W., Kuznetsov, O., Buongiorno, G., Hsuing, H. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994, 151: 1463-7.
14. Davidson, D., Palfai, T., Bird, C., Swift, R. Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 1999, 23: 193-203.
15. O'Malley, S., Jaffe, A.J., Chang, G. et al. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 1992, 49: 881-7.
16. Volpicelli, J.R., Alterman, A.I., Hayashida, M., O'Brien, C.P. Naltrexone in the treatment of alcoholism. (1992). Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 1992, 49: 876-80.
17. Monti, P.M., Rohsenow, D.J., Swift, R.M. et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001, 25: 1634-47.
18. Kranzler, H.R., Modesto-Lowe, V., Van Kirk, J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 2000, 22: 493-503.
19. Krystal, J.H., Cramer, J.A., Krol, W.F., Kirk, G.F., Rosenheck, R.A. Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001, 345: 1734-9.
20. Garbutt, J.C., West, SL., Carey T.S., Lohr, K.N., Crews, F.T. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA 1999, 281: 1318-25.
21. Kranzler, H. and Van Kirk, J. Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta analysis. Alcohol Clin Exp Res 2001, 25: 1335-41.
22. Combine Study Research Group. Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE) study): A pilot feasibility study. Alcohol Clin Exp Res 2003, 27: 1123-31.
23. Johnson, B.A., Ait-Doud, N., Bowden, C.L. et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet 2003, 361: 1677-85.
24. Johnson, B.A., Ait-Dowd, N. Neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Psychopharmacology 2000, 149: 327-44.
25. Litten, R.Z., Allen, J.P. Reducing the desire to drink. Pharmacology and neurobiology. Recent Dev Alcohol 1993, 11: 325-44.
26. Heimer, L., Alheid, G.F., de Olmos, J.S., Groenewegen, H.J., Haber, S.N., Harlan, R.E., Zahm, D.S. The accumbens: Beyond the core-shell dichotomy. J Neuropsych Clin Neurosci 1997, 9: 354-81.
27. Noble, E. The gene that rewards alcoholism. Scientific Am Sci Med 1996, 3: 52-61.
28. Robinson, T.E., Berridge, K.C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Rev 1993, 18: 247-291.
29. Wise, R.A. Neuroleptics and operant behavior: The anhedonia hypothesis. Behav Brain Sci 1982, 5: 39-87.
30. Benjamin, D., Grant, E.R., Pohorecky, L.A. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993, 621: 137-40.
31. 3 receptors. J Neurosci 1998, 18: 6528-38.
32. Murphy, J.M., McBride, W.J., Lumeng, L., Li, T.K. Contents of monoamines in forebrain regions of alcohol-preferring (P) and non-preferring (NP) lines of rats. Pharmacol Biochem Behav 1987, 26: 389-92.
33. Gongwer, M.A., Murphy, J.M., McBride, W.J., Lumeng, L., Li, T.K. Regional brain contents of serotonin, dopamine and their metabolites in the selectively bred high- and low-alcohol drinking lines of rats. Alcohol 1989, 6: 317-20.
34. Samson, H.H., Hodge, C.W., Tolliver, G.A., Haraguchi, M. Effect of dopamine agonists and antagonists on ethanol-reinforced behavior: the involvement of the nucleus accumbens. Brain Res Bull 1993, 30: 133-41.
35. Rassnick, S., Pulvirenti, L., Koob, G.F. Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. Psychopharmacology 1992, 109: 92-8.
36. McBride, W.J., Murphy, J.M., Lumeng, L., Li, T.K. Serotonin, dopamine and GABA involvement in alcohol drinking of selectively bred rats. Alcohol 1990, 7:199-205.
37. 2 dopamine receptor agents on ethanol consumption in the high-alcohol-drinking (HAD) line of rats. Alcohol 1993, 10: 207-12.
38. Balldin, J., Berggren, U.C., Lindstedt, G. Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism. Alcohol Clin Exp Res 1992, 16: 71-4.
39. 2 dopamine receptor function in alcoholism. Drug Alcohol Depend 1993, 32: 159-62.
40. 2 dopamine receptor function as neuroendocrinologically assessed with apomorphine. Drug Alcohol Depend 1995, 40: 49-53.
41. Heinz, A. Dopaminergic dysfunction in alcoholism and schizophrenia-psychological and behavioral correlates. Eur Psychiatry 2002, 17: 9-16.
42. Modell, J.G., Mountz, J.M., Glaser, F.B., Lee, J.Y. Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. Alcohol Clin Exp Res 1993, 17: 234-40.
43. Shaw, G.K., Waller, S., Majumdar, S.K., Latham, C.J., Dunn, G. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994, 165: 515-23.
44. Hutchinson, K., Swift, R., Attias, E., Monti, P., Roshenow, D. Effects of olanzapine on cue induced craving in moderate to heavy social drinkers. Alcohol Clin Exp Res 1998, 22: 662A.
45. Drake, R.E., Xie, H., McHugo, G.J., Green, A.I. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000, 26: 441-9.
46. Hutchison, K.E., Swift, R., Rohsenow, D.J., Monti, P.M., Davidson, D., Almeida, A. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology 2001, 155: 27-34.
47. Hutchison, K.E., Wooden, A., Swift, R.M., Smolen, A., McGeary, J., Adler, L., Paris, L. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 2003, 28: 1882-8.
48. Tamion, F., Petit, J., Massari, P. et al. Malignant neuroleptic syndrome during tiapride treatment. J Toxicol Clin Exp 1990, 10: 461-7.
49. Delmeire, F. Tiapridal. Acta Psychiatr Belg 1980, 80: 191-201.
50. Sussman, N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 2003, 23(3, Suppl 1): S21-6.
51. Osser, D.N., Najarian, D.M., Dufresne, R.L. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999, 60: 767-70.
52. Heiskanen, T., Niskanen, L., Lyytikainen, R., Saarinen, P., Hintikka, J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003, 64: 575-9.
53. Feldman, J. Psychopharmacology. Clozapine and agranulocytosis. Psychiatr Serv 1996, 47: 1177-8.
54. Siris, S.G. Pharmacological treatment of substance-abusing schizophrenia patients. Schizophr Bull 1990, 16: 111-22.
55. McEvoy, J.P., Freudenreich, O., Levin, E., Rose, J.E. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 1995, 119: 124-6.
56. Hoyer, D., Boddeke, H.W. Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 1993, 14: 270-5.
57. Pulvirenti, L., Koob, G.F. Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol Sci 1994, 15: 374-9.
58. Bono, G., Balducci, C., Richelmi, P., Koob, G.F., Pulvirenti, L. Dopamine partial receptor agonists reduce ethanol intake in the rat. Eur J Pharmacol 1996, 296: 233-8.
59. Izzo, E., Orsini, C., Koob, G.F., Pulvirenti, L. A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule. Pharmacol Biochem Behav 2001, 68:701-8.
60. 2-like receptor partial agonist terguride in squirrel monkeys. Psychopharmacology 2003, 166: 298-305.
61. Diana, M., Pistis, M., Carboni, S., Gessa, G.L., Rossetti, Z.L. Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: electrophysiological and biochemical evidence. Proc Natl Acad Sci USA 1993, 90: 7966-9.
62. Smith, A., Parson, L.H., Pich, E.M. et al. Ethanol modifies extracellular levels of dopamine, serotonin and corticotropin releasing factor in the limbic forebrain: studies in rats with different histories of ethanol exposure. Soc Neurosci Abstr 1994, 20: 1614.
63. Lovinger, D. Serotonin's role in alcohol's effects on the brain. Alcohol Health Res World 1997, 21: 114-20.
64. Ciccocioppo, R. The role of serotonin in craving: from basic research to human studies. Alcohol 1999, 34: 244-53.
65. LeMarquand, D., Pihl, R.O., Benkelfat, C. Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiatry 1994, 36: 326-37.
66. Myers, R.D., Martin, G.E. The role of cerebral serotonin in the ethanol preference of animals. Ann NY Acad Sci 1973, 215: 135-44.
67. Schuckit, M.A. Recent developments in the pharmacotherapy of alcohol-dependence. J Consult Clin Psychol 1996, 64: 669-76.
68. Kranzler, H.R., Burleson, J.A., Del Boca, F.K. et al. Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry 1994, 51: 720-31.
69. Sellers, E.M., Higgins, G.A., Sobell, M.B. 5-HT and alcohol abuse. Trends Pharmacol Sci 1992, 13: 16-75.
70. Swift, R.M. Medication and alcohol craving. Alcohol Health Res World 1999, 23: 207-13.
71. Agren, H. Life at risk: Markers of suicidality in depression. Psychiatr Dev 1983, 1: 87-103.
72. Banki, C.M., Molnar, G. Cerebrospinal fluid 5-hydroxyindoleacetic acid as an index of central serotonergic processes. Psychiatry Res 1981, 5: 23-32.
73. Tollefson, G.D., Montague-Close J., Tollefson, S.L. Treatment of comorbid generalizes anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 1992, 12: 19-26.
74. Malcolm, R., Anton, R.F., Randall, C.L., Johnston, A., Brady, K., Thevos, A. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992, 16: 1007-13.
75. Fawcett, J., Kravitz, H.M., McGuire, M. et al. Pharmacological treatments for alcoholism: revisiting lithium and considering buspirone. Alcohol Clin Exp Res 2000, 24: 666-74.
76. Malec, T.S., Malec, E.A., Dongier, M. Efficacy of buspirone in alcohol dependence: A review. Alcohol Clin Exp Res 1996, 20: 853-8.
77. Pettinati, H.M. Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. Alcohol Clin Exp Res 1996, 20 (7, Suppl): 23A-29A.
78. Naranjo, C.A., Chu, A.Y., Tremblay, L.K. Neurodevelopmental liabilities in alcohol dependence: central serotonin and dopamine dysfunction. Neurotox Res 2002, 4: 43-61.
79. Cornelius, J.R., Salloum, I.M., Ehler, J.G. et al. Fluoxetine in depressed alcoholics. A double-blind placebo controlled trial. Arch Gen Psychiatry 1997, 23: 193-203.
80. Kranzler, H.R., Burleson, J.A., Korner, P. et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995, 152: 391-7.
81. Pettinati, H., Volpllicelli, J., Kranzler, H. et al. Sertraline treatment for alcohol dependence. Interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000, 24: 1041-9.
82. Johnson, B.A. Serotonergic agents and alcoholism treatment: rebirth of the subtype concept - an hypothesis. Alcohol Clin Exp Res 2000, 24: 1597-601.
83. Johnson, B.A., Roache, J. et al. Ondansetron for reduction of drinking among biologically predisposed patients: A randomized controlled trial. JAMA 2000, 284: 963-71.
84. Otsuka Pharmaceutical Co. Ability prescribing information. Otsuka Pharmaceutical Co. Ltd, Tokyo 2002.
85. 2 receptor antagonistic activity. J Pharmacol Exp Ther 1995, 274: 329-36.
86. 2 receptors. J Pharmacol Exp Ther 2002, 302: 381-9.
87. Shapiro, D.A., Renock, S., Arrington, E. et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28: 1400-11.
88. Balldin, J., Berglund, M., Borg, S. et al. A 6-month controlled naltrexone study: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 2003, 27: 1142-9.
89. Semba, J., Watanabe, A., Kito, S., Toru, M. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 1995, 34: 785-91.
90. 2-like receptor partial agonist terguride in squirrel monkeys. Psychopharmacology 2003, 166: 298-305.
91. Glennon, R.A., Dukat, M. Serotonin receptor subtypes. In: Psychopharmacology: The Fourth Generation of Progress. Bloom, F.E.; Kupfer, D.J. (Eds). Raven Press: New York 1995, 415-29.
92. Kasper, S., Taucher, J., Kufferle, B., Barnas, C., Pezawas, L., Quiner, S. Dopamine-and serotonin receptors in schizophrenia: results of imaging studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999, 249 (S4): 83-9.
93. Raheja, R.K., Bharwani, I., Penetrante, A.E. Efficacy of risperidone for behavioral disorders in the elderly: A clinical observation. J Geriatr Psychiatry Neurol 1995, 8: 159-61.
94. 2 antagonist FG 5893. Alcohol 1993, 10: 243-8.
95. 2C receptors and their atypical regulation properties. Life Sci 2003, 72: 2429-49.
96. Hamel, E. The biology of serotonin receptors: focus on migraine pathophysiology and treatment. Can J Neurol Sci 1999, 26(Suppl. 3): S2-6.
97. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000, 57: 75-81.
98. 2 receptor blockade by amperozide suppresses ethanol drinking in genetically preferring rats. Pharmacol Biochem Behav 1993, 45: 741-7.
99. Johnson, B.A., Jasinski, D.R., Galloway, G.P. et al. Ritanserin in the treatment of alcohol dependence - a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology 1996, 128: 206-15.
100. 1A/2A receptor drug FG5938 suppresses alcohol drinking while enhancing feeding in P rats. Alcohol 1996, 3: 521-7.
101. Roberts, A.J., McArthur, R.A., Hull, E.E., Post, C., Koob, G.F. Effects of amperozide, 8-OH-DPAT, and FG 5974 on operant responding for ethanol. Psychopharmacology 1998, 137: 25-32.
102. Carson, W.H., Saha, A.R., McQuade, R.D. et al. A maintenance study of aripiprazole. Presentation at the American College of Neuropsychopharmacology Puerto Rico, December 2002.
103. Kane, J.M., Carson, W.H., Saha, A.R. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002, 63: 763-71.
104. Petrie, J.L., Saha, A.R., McEvoy, J.P. Aripiprazole, a new atypical antispycotic: Phase 2 clinical trials. Eur Neuropsychopharmacol 1997, 7: S227.
105. Buckley, P. Aripiprazole: Efficacy and tolerability profile of a novel-acting atypical antipsychotic. Drugs Today 2003, 39: 145-51.
106. Tecott, L.H., Sun, L.M., Akana, S.F. et al. Expression of a serotonin-gated ion channel in embryonic neural and nonneural tissues. Mol Cell Neurosci 1995, 6: 43-55.
107. Cornblatt, B., Green, M.F., Carson, W. et al. A comparison of cognitive performance on aripiprazole and olanzapine. Int J Neuropsychopharmacol 2002, 5(S1): S185.
108. Birt, J. Management of weight gain associated with antipsychotics. Ann Clin Psychiatry 2003, 15: 49-58.
109. 1 receptor deleted mice. Neurosci Lett 2003, 343: 216-8.
110. Yeomans, M.R., Gray, R.W. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 2002, 26: 713-28.
111. Volpicelli, J.R., Alterman, A.I. et al. Naltrexone in the treatment of alcoholism. (1992). Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 1992, 49: 876-80.
112. Market analysis. Nat Rev Drug Discov 2003, 2: 427-8.
113. Stahl, S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1. "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001, 62: 841-2.